Expert Panel Agrees: Drug Price Reform Is Much Needed

Reforms are needed high up within the drug distribution chain, concluded a panel of pharmaceutical professionals at the Oncology Market Access & Pricing conference held in Philadelphia this week by eyeforpharma.
 
BY TONY HAGEN @oncobiz
PUBLISHED: JUNE 19, 2017
Reforms are needed high up within the drug distribution chain, concluded a panel of pharmaceutical professionals at the Oncology Market Access & Pricing conference held in Philadelphia this week by eyeforpharma.

Legal actions on drug pricing and access are putting increasing pressure on drug manufacturers to join the reform, and there are signs that the administration of President Donald Trump is poised to take executive action on a policy to streamline genetic drug access and spur CMS to start approving value-based contracts with drug manufacturers, said Jayson S. Slotnik, moderator of the panel and the founder of Health Policy Strategies, a Washington DC-based consulting firm.

Addressing an audience of pharma industry professionals, Slotnik said the drug pricing issue has intensified this year partly because of a class-action racketeering lawsuit lodged against Mylan for the strategies it employed that dramatically increased the cost of the anti-allergy device EpiPen. The suit alleges that the price of EpiPen was raised 17 times in a decade, from $90 to $600.

Self-serving practices in the pharmaceutical industry are not the whole picture, he said. There is unfairness and misunderstanding as well, ranging from the heavy financial risk providers in the Oncology Care Model are being asked to undertake to the unwillingness of payers to fully accept drug manufacturers desire to recoup billions of dollars in research and development costs. These factors make it more difficult to deliver value in oncology; however, “The one thing we all try to seek is a good outcome for the patient,” Slotnik said.

The panel discussion included Burt Zweigenhaft, former president of the National Association of Specialty Pharmacy. He recalled a time when oncologists earned an average of $1 million a year and now receive about $400,000. More prior authorizations required for drug use and protocols for therapy plans have also changed the payment picture. The “buy and bill” days, when physicians had tremendous freedom to prescribe, are over, he said.

Some reform programs may not survive the transition to precision medicine, he said. For example, the bundling of costs for established therapeutic patterns has been a tool in the value-based armamentarium, but this relies on the ability to accurately estimate costs. Such a tool will likely become obsolete as potentially thousands of biomarkers for cancer are discovered and therapy is increasingly targeted. The variation will vastly complicate treatment protocols for doctors and patients, he said.

“That’s going to bring even more subtypes and a lot more heat over drug costs, utilization, and total cost of treatment.” As potential variations in treatment balloon, payers and providers will shy away from bundled care models that force them to take downside financial risk on total costs of care. “You only bet on what you know.”

Amid the pressure on pricing, specialty pharmacy has grown enormously and has taken on some of the roles traditionally handled by physicians, the panelists said. These intermediaries in the drug distribution chain now are increasingly designing programs that do more than simply fill prescriptions. The most sophisticated of these systems follow up with patients and monitor their dosing, how much medication they may have left, whether they are refilling, how they are affected by drugs, and helping to arrange financing for medication, said panelist Anita Dopkisky, director of national accounts for Walgreens and a former clinician.



Talk about this article with other patients, caregivers, and advocates in the General Financial Topics CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
Complementary Therapies for Cancer Treatment Are Coming of Age
Nonmedical treatments offering physical and psychosocial relief are gaining respect in the medical community.
Chemo Brain Barb
Two-time cancer survivor shares the frustrations of struggling with chemo brain. And yes, it's real.
Friendships of Cancer
If cancer gave us one gift in life, it was the friendships formed along the way.
Related Videos
Preserving Eyebrows During Chemotherapy Treatment
Renata Marie Vestevich, founder and developer of Essential Eyebrow Solution (EES), discusses how this topical solution may be able to help patients keep their eyebrow hair while undergoing chemotherapy.
Does Age Affect Cancer Genomics?
Garrett Frampton, associate director of Cancer Genomics at Foundation Medicine, discusses recent research about genetic mutations that are more common in certain age groups.  
Facing Advanced Cancer's Struggles With CALM
Gary Rodin, M.D., head of the Department of Supportive Care at Princess Margaret Cancer Centre, in Toronto, Canada, discusses CALM, an intervention designed to help patients with advanced-stage cancer cope and talk about their concerns.
x
//For side ad protocol